Company news

MoonLake Immunotherapeutics news in 2025

MoonLake Immunotherapeutics's news releases, calls and decks from 2025, newest first.

View company

MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab

November 4, 2025

MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering

November 4, 2025

MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody® sonelokimab

September 27, 2025

MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update

August 4, 2025

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

May 11, 2025

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29

April 24, 2025

MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates

April 2, 2025

MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

February 25, 2025

MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

January 7, 2025

Decks in 2025